Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jul 24

PMID 34299225

Citations 12

Authors

Weronika Bielka

Agnieszka Przezak

Andrzej Pawlik

Affiliations

Soon will be listed here.

Abstract

COVID-19 infection poses an important clinical therapeutic problem, especially in patients with coexistent diseases such as type 2 diabetes. Potential pathogenetic links between COVID-19 and diabetes include inflammation, effects on glucose homeostasis, haemoglobin deoxygenation, altered immune status and activation of the renin-angiotensin-aldosterone system (RAAS). Moreover, drugs often used in the clinical care of diabetes (dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, metformin and insulin) may influence the course of SARS-CoV-2 infection, so it is very important to verify their effectiveness and safety. This review summarises the new advances in diabetes therapy and COVID-19 and provides clinical recommendations that are essential for medical doctors and for patients suffering from type 2 diabetes.

Citing Articles

Correlation of diabetes and adverse outcomes in hospitalized COVID-19 patients admitted to a tertiary hospital in China during a small-scale COVID-19 outbreak.

Li Y, Li G, Li J, Luo Z, Lin Y, Lan N PeerJ. 2025; 13:e18865.

PMID: 39886017 PMC: 11781264. DOI: 10.7717/peerj.18865.

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences.

Froldi G Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675438 PMC: 11054066. DOI: 10.3390/ph17040478.

SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?.

Zimmermann P, Sourij H, Aberer F, Rilstone S, Schierbauer J, Moser O J Cardiovasc Dev Dis. 2023; 10(12).

PMID: 38132646 PMC: 10744331. DOI: 10.3390/jcdd10120478.

Insight on Infections in Diabetic Setting.

Pari B, Gallucci M, Ghigo A, Brizzi M Biomedicines. 2023; 11(3).

PMID: 36979949 PMC: 10046483. DOI: 10.3390/biomedicines11030971.

COVID-19: Diabetes Perspective-Pathophysiology and Management.

Dallavalasa S, Tulimilli S, Prakash J, Ramachandra R, Madhunapantula S, Veeranna R Pathogens. 2023; 12(2).

PMID: 36839456 PMC: 9967788. DOI: 10.3390/pathogens12020184.

References

Dekkers C, Petrykiv S, Laverman G, Cherney D, Gansevoort R, Heerspink H . Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018; 20(8):1988-1993. PMC: 6055757. DOI: 10.1111/dom.13301. View

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Sromova L, Busek P, Posova H, Potockova J, Skrha P, Andel M . The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016; 118:183-92. DOI: 10.1016/j.diabres.2016.06.020. View

Prattichizzo F, La Sala L, Ryden L, Marx N, Ferrini M, Valensi P . Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol. 2019; 26(2_suppl):73-80. DOI: 10.1177/2047487319880040. View

Krejner-Bienias A, Grzela K, Grzela T . DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?. Arch Immunol Ther Exp (Warsz). 2021; 69(1):1. PMC: 7850901. DOI: 10.1007/s00005-020-00602-5. View

Krejner-Bienias A, Grzela K, Grzela T . Do novel drugs for diabetes help in COVID-19? Another brick in the wall?. J Diabetes. 2020; 12(9):703-704. PMC: 7272829. DOI: 10.1111/1753-0407.13050. View

Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y . Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020; 63(10):2102-2111. PMC: 7347402. DOI: 10.1007/s00125-020-05209-1. View

Doupis J, Avramidis K . Managing Diabetes During the COVID-19 Pandemic. Eur Endocrinol. 2020; 16(2):85-87. PMC: 7572158. DOI: 10.17925/EE.2020.16.2.85. View

Libby P, Simon D . Inflammation and thrombosis: the clot thickens. Circulation. 2001; 103(13):1718-20. DOI: 10.1161/01.cir.103.13.1718. View

10.

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J, Turner A . Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10):1456-1474. PMC: 7188049. DOI: 10.1161/CIRCRESAHA.120.317015. View

11.

Roca-Ho H, Riera M, Palau V, Pascual J, Soler M . Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. Int J Mol Sci. 2017; 18(3). PMC: 5372579. DOI: 10.3390/ijms18030563. View

12.

Bassaganya-Riera J, Song R, Roberts P, Hontecillas R . PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol. 2010; 23(4):343-52. DOI: 10.1089/vim.2010.0016. View

13.

Nauck M, Meier J . MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. Eur J Endocrinol. 2019; 181(6):R211-R234. DOI: 10.1530/EJE-19-0566. View

14.

Yang J, Lin S, Ji X, Guo L . Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2009; 47(3):193-9. PMC: 7088164. DOI: 10.1007/s00592-009-0109-4. View

15.

Santos R, Sampaio W, Alzamora A, Motta-Santos D, Alenina N, Bader M . The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018; 98(1):505-553. PMC: 7203574. DOI: 10.1152/physrev.00023.2016. View

16.

Wang J, Meng W . COVID-19 and diabetes: the contributions of hyperglycemia. J Mol Cell Biol. 2020; 12(12):958-962. PMC: 7543402. DOI: 10.1093/jmcb/mjaa054. View

17.

Cure E, Cumhur Cure M . Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. Diabetes Metab Syndr. 2020; 14(4):349-350. PMC: 7159862. DOI: 10.1016/j.dsx.2020.04.019. View

18.

Bornstein S, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld A . Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020; 8(6):546-550. PMC: 7180013. DOI: 10.1016/S2213-8587(20)30152-2. View

19.

Chowdhury T . Diabetes and COVID-19: Diseases of racial, social and glucose intolerance. World J Diabetes. 2021; 12(3):198-205. PMC: 7958476. DOI: 10.4239/wjd.v12.i3.198. View

20.

Hahn K, Ejaz A, Kanbay M, Lanaspa M, Johnson R . Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016; 12(12):711-712. DOI: 10.1038/nrneph.2016.159. View